BACKGROUND: Triple-negative breast cancer is estimated to account for 15%-20% of all patients with breast cancer and is considered as a prognostically unfavorable subset. The aim of this study is to evaluate the prognostic impact of various molecular factors in patients with triple-negative breast cancer. PATIENTS AND METHODS: Tumor specimens from 109 patients with receptor-negative (estrogen receptor and progesterone receptor) breast cancer were analyzed for mitogen-activated protein kinase (MAPK), epidermal growth factor receptor (EGFR) and phosphoinositol-3-kinase (PI3K) expression by immunohistochemistry. The prognostic significance of these molecular factors, in addition to various prognostic variables, was investigated. RESULTS: Fifteen (13.8%), 38 (34.9%) and 33 patients (30.3%) had positive staining for EGFR, MAPK and PI3K, respectively. MAPK was associated with anthracycline resistance (P = 0.008) and lower MAPK score was significantly associated with shorter disease-free survival (P = 0.029). Survival following relapse was significantly worse for those with a higher MAPK score (P = 0.03). CONCLUSION: MAPK is a significant prognostic and predictive factor in patients with triple-negative breast cancer. Furthermore, the level of staining among those with a positive MAPK expression may play a prognostic role at different stages of relapse. Further translational research is required to elucidate molecular mechanisms of tumor proliferation in this subset of patients.
BACKGROUND: Triple-negative breast cancer is estimated to account for 15%-20% of all patients with breast cancer and is considered as a prognostically unfavorable subset. The aim of this study is to evaluate the prognostic impact of various molecular factors in patients with triple-negative breast cancer. PATIENTS AND METHODS: Tumor specimens from 109 patients with receptor-negative (estrogen receptor and progesterone receptor) breast cancer were analyzed for mitogen-activated protein kinase (MAPK), epidermal growth factor receptor (EGFR) and phosphoinositol-3-kinase (PI3K) expression by immunohistochemistry. The prognostic significance of these molecular factors, in addition to various prognostic variables, was investigated. RESULTS: Fifteen (13.8%), 38 (34.9%) and 33 patients (30.3%) had positive staining for EGFR, MAPK and PI3K, respectively. MAPK was associated with anthracycline resistance (P = 0.008) and lower MAPK score was significantly associated with shorter disease-free survival (P = 0.029). Survival following relapse was significantly worse for those with a higher MAPK score (P = 0.03). CONCLUSION: MAPK is a significant prognostic and predictive factor in patients with triple-negative breast cancer. Furthermore, the level of staining among those with a positive MAPK expression may play a prognostic role at different stages of relapse. Further translational research is required to elucidate molecular mechanisms of tumor proliferation in this subset of patients.
Authors: Lara H El Touny; Anthony Vieira; Arnulfo Mendoza; Chand Khanna; Mark J Hoenerhoff; Jeffrey E Green Journal: J Clin Invest Date: 2013-12-09 Impact factor: 14.808
Authors: S Gholami; C-H Chen; S Gao; E Lou; S Fujisawa; J Carson; J E Nnoli; T-C Chou; J Bromberg; Y Fong Journal: Cancer Gene Ther Date: 2014-06-13 Impact factor: 5.987
Authors: Tianhong Li; Mengye Guo; William J Gradishar; Joseph A Sparano; Edith A Perez; Molin Wang; George W Sledge Journal: Breast Cancer Res Treat Date: 2012-05-01 Impact factor: 4.872
Authors: Chang Hoon Song; So Yeon Park; Keun-Yong Eom; Jee Hyun Kim; Sung-Won Kim; Jae Sung Kim; In Ah Kim Journal: Breast Cancer Res Date: 2010-03-12 Impact factor: 6.466
Authors: A B D'Assoro; T Liu; C Quatraro; A Amato; M Opyrchal; A Leontovich; Y Ikeda; S Ohmine; W Lingle; V Suman; J Ecsedy; I Iankov; A Di Leonardo; J Ayers-Inglers; A Degnim; D Billadeau; J McCubrey; J Ingle; J L Salisbury; E Galanis Journal: Oncogene Date: 2013-01-21 Impact factor: 9.867
Authors: Edith A Perez; Alvaro Moreno-Aspitia; E Aubrey Thompson; Cathy A Andorfer Journal: Breast Cancer Res Treat Date: 2010-01-22 Impact factor: 4.872
Authors: Chandra Bartholomeusz; Ana M Gonzalez-Angulo; Ping Liu; Naoki Hayashi; Ana Lluch; Jaime Ferrer-Lozano; Gabriel N Hortobágyi Journal: Oncologist Date: 2012-05-14